Idiopathic Pulmonary Fibrosis

Latest News in Idiopathic Pulmonary Fibrosis

June 6, 2024

Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis – Business Wire

May 27, 2024

EPB41L3 is a prognostic marker in idiopathic pulmonary fibrosis – BioWorld Online

May 24, 2024

Body mass index is associated with clinical outcomes in idiopathic pulmonary fibrosis – Nature.com

April 24, 2024

Leech extract alleviates idiopathic pulmonary fibrosis by TGF-β1/Smad3 signaling pathway – ScienceDirect.com

April 17, 2024

Prognostic implication of 1-year decline in diffusing capacity in newly diagnosed idiopathic pulmonary fibrosis – Nature.com

120 Active Idiopathic Pulmonary Fibrosis Clinical Trials

As of October 8, 2024

Source: clinicaltrials.gov

LOCATE

CLINICAL TRIALS

BROWSE

FDA-approved DRUGS

FIND

A DOCTOR EXPERT™

WHAT IS

CONGRESS DOING?